BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221018
DTEND;VALUE=DATE:20221021
DTSTAMP:20260515T212146
CREATED:20220714T094650Z
LAST-MODIFIED:20220714T094650Z
UID:34667-1666051200-1666310399@www.pharmajournalist.com
SUMMARY:Operationalise: Early Access Programmes Summit Europe
DESCRIPTION:With over 100 early and managed access\, compassionate use\, and named patient programmes running across the continent\, the Operationalise: Early Access Programmes Summit Europe has been carefully curated to help you address difficulties with supply\, logistics and cost\, challenges with navigating European regulations\, and planning and running equitable\, patient-first early access programmes. \nDownload the full event guide to view the world-class speaker faculty of over 20 experienced EAP leaders\, who will be sharing their insights through best-practice case studies. \nImmerse yourself in three days of interactive sessions and discuss your peers’ approaches to involving the patient voice\, engaging different stakeholders\, planning considerations for a successful EAP and more. \nWith a specific focus on real-world case studies and practical applications\, join us to gain a greater understanding and clarity of the end-to-end management of running an early access programme in Europe.
URL:http://www.pharmajournalist.com/event/operationalise-early-access-programmes-summit-europe/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221018
DTEND;VALUE=DATE:20221021
DTSTAMP:20260515T212146
CREATED:20220622T094513Z
LAST-MODIFIED:20220622T094513Z
UID:34491-1666051200-1666310399@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy Immunogenicity Summit
DESCRIPTION:The 3rd Annual Gene Therapy Immunogenicity Summit is industry’s definitive forum enabling you to better modulate\, measure and predict the immune response to your gene therapy candidate. \nIn the context of ever-increasing gene therapy clinical activity and uncertainty around challenges posed by immune responses to delivery\, this summit will unite large pharma and innovative biotech’s to ensure that you’re up to speed on the latest approaches to evaluate and overcome pre-existing immunity to AAV vectors\, understand how immune-modulatory strategies can help to ensure efficacy and safety and learn the reality of regulatory expectations around immunological assays. \nIncorporating insights from leading immunological\, bioanalytical\, and translational experts\, this is your opportunity to gain extensive technical information on the contrasts between immunogenicity encountered across organs and administration routes\, how models can be enhanced to enable comparative immunology between species and what the latest clinical data tells us about how to adapt existing clinical mitigation strategies to address immunogenicity. \nWith 35+ industry-based speakers covering pre-clinical and clinical immunogenicity challenges over 2 tracks and 3 packed days of content\, don’t miss your chance to join over 100+ fellow industry experts to network in person and share your research as you seek new and improved ways of predicting immunogenicity in the clinic to ultimately ensure the safety and efficacy of gene therapies. \nTo know more visit: https://ter.li/acp4lt
URL:http://www.pharmajournalist.com/event/3rd-annual-gene-therapy-immunogenicity-summit/
LOCATION:The Colonade\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221018
DTEND;VALUE=DATE:20221021
DTSTAMP:20260515T212146
CREATED:20220620T112738Z
LAST-MODIFIED:20220620T112738Z
UID:34479-1666051200-1666310399@www.pharmajournalist.com
SUMMARY:Process Development for Cell Therapies Summit
DESCRIPTION:“The Process is the Product” – Drive Process Excellence at the Only Summit Dedicated to Process Development for Cell Therapies \n \nAs momentum continues to build for the cell therapy industry\, process development looms as a huge potential bottleneck to overcome. The inaugural Process Development for Cell Therapies Summit will give you unprecedented access to an industry melting pot of process development tools and experience to drive down cost of goods\, maximize scalability and achieve regulatory compliance. \nJoin your peers who will all be gathering to learn how to identify and plug platform gaps for automation\, global scale-out\, faster phase development\, increased affordability\, and more! \nWith 20+ case studies being presented\, you will come away with tried and tested strategies informed by industry leaders such as BMS\, Kite\, Lyell Immunopharma\, and Immatics Biotechnologies. There is no other event of this kind which is focused specifically on Process Development for Cell Therapy\, delivering case studies to provide actionable insights. \nNow is the time to gather with the industry gurus to unpick shared challenges in process development and share best practices to de-silo the industry and bring better therapies to patients faster. \nFind out more about the meeting\, who’s attending and what you could learn by downloading the latest event guide: https://ter.li/lbtpp0 \nWe look forward to welcoming you to Boston in October!
URL:http://www.pharmajournalist.com/event/process-development-for-cell-therapies-summit/
LOCATION:Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221018
DTEND;VALUE=DATE:20221021
DTSTAMP:20260515T212146
CREATED:20220613T094420Z
LAST-MODIFIED:20220624T095129Z
UID:34406-1666051200-1666310399@www.pharmajournalist.com
SUMMARY:Innate Killer Summit Europe
DESCRIPTION:The Innate Killer Summit Europe gathers 80+ key European Gamma Delta T\, NK\, and Macrophage developers in October to chase the holy grail of efficacious\, off-the-shelf\, solid tumour immunotherapies through innate cell targeting and engineering. \nSeize your chance to network with innate immune trailblazers from the likes of Sanofi\, Takeda\, Gamida Cell\, Glycostem and Bayer and gain a comprehensive overview of candidates to inform your strategic development and progress the field together with an industry brain trust. \nBridging the gap between the technicalities of early discovery through to process optimisation and leaping regulatory hurdles\, this is the must-attend meeting to accelerate safe and scalable therapies in Europe. \nTo learn more\, visit: www.innate-killer-europe.com
URL:http://www.pharmajournalist.com/event/innate-killer-summit-europe/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221011
DTEND;VALUE=DATE:20221014
DTSTAMP:20260515T212146
CREATED:20220712T103251Z
LAST-MODIFIED:20220713T075908Z
UID:34648-1665446400-1665705599@www.pharmajournalist.com
SUMMARY:3rd Commercializing Flow Chemistry Summit 2022
DESCRIPTION:With the exciting proof-of-concept milestones from Phlow\, commitments from global regulatory agencies\, and breakthroughs from the likes of AbbVie\, AstraZeneca\, Merck and BMS\, over the last 12 months flow chemistry continues to take off at an exponential rate\, further evidenced by the significant investments from CDMOs such as Almac\, Corden Pharma\, Sterling and Cambrex. \nShowcasing the steep progress being made whilst addressing the field’s most front-of-mind challenges to enable the full potential of continuous chemistry to come to fruition\, the 3rd Annual Commercializing Flow Chemistry Summit is back to bridge the gap between academic and industry innovation as your only meeting bringing both technical and strategic flow chemistry intelligence under one roof in Boston this October. \nUniting 100+ Process Development\, Chemistry & Control\, PAT\, CMC\, Continuous Manufacturing and Engineering experts across biopharma\, academia\, CDMO and fine chemical & API organizations for the first time in person\, this is your prime opportunity to turn flow chemistry into industrial applications and implement advanced process control strategies to ensure product quality and meet regulatory expectations. \nFor practical takeaways across technical chemical engineering\, process development\, batch to flow transitions\, novel chemistries\, scale-up\, PAT implementation & more\, reduce your development cycle and enhance operational efficiency by attending the 3rd CFC Summit 2022! \nTo know more visit: https://ter.li/pqcevv
URL:http://www.pharmajournalist.com/event/3rd-commercializing-flow-chemistry-summit-2022/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221011
DTEND;VALUE=DATE:20221014
DTSTAMP:20260515T212146
CREATED:20220630T100728Z
LAST-MODIFIED:20220630T100728Z
UID:34561-1665446400-1665705599@www.pharmajournalist.com
SUMMARY:10th IMPACCT Real World Evidence Summit
DESCRIPTION:Returning in person for its 10th year anniversary\, the IMPACCT: Real World Evidence Summit will deep dive into the use of RWE for regulatory submissions and improved clinical trial design to help you navigate the regulatory landscape. \nFollowing recent FDA and EMA guidelines\, this comprehensive industry-led forum will address how drug developers can leverage RWE from beginning to end of study\, ensure clinical studies are well-designed\, include appropriate protections for their patients and upload data integrity. \nJoin 100+ senior leaders in RWE\, RWD\, real world analytics experts & epidemiologists from pharma and biotech to take part in this three day summit with over 18 hours of exclusive content. \nTo know more visit: https://ter.li/tymfzh
URL:http://www.pharmajournalist.com/event/10th-impacct-real-world-evidence-summit/
LOCATION:Crowne Plaza Woburn\, 15 Middlesex Canal Park Rd\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221011
DTEND;VALUE=DATE:20221014
DTSTAMP:20260515T212146
CREATED:20220617T103229Z
LAST-MODIFIED:20220617T103229Z
UID:34419-1665446400-1665705599@www.pharmajournalist.com
SUMMARY:Reuters Events: Pharma 2022
DESCRIPTION:Comprehensive frameworks for equitable access and accelerated digital transformations are soon to be realized. But progress is slowing\, risking a return to the old model plagued by persistent health disparities. \nTo thrive\, each strategy and tactic must be centred with a whole-human approach\, ensuring an agile\, patient-driven\, technology-enabled change. \nYou must advance intelligent automation\, delivering value-driven content that enhance patient and HCP experiences\, activate new skillsets for field teams to strengthen clinical practices\, whilst collaborating with stakeholders – and competitors – to drastically improve equitable access to the vast galaxy of innovation improving patient outcomes and propelling commercial growth. \nReuters Events: Pharma 2022 (11-13 October\, Nice France – formerly eyeforpharma Barcelona) is the only place where patient experts\, leading solution providers\, and pharma changemakers – from commercial\, marketing\, medical affairs\, patient engagement\, market access and RWE – commit to business transformation as the catalyst for maximum patient impact. \nTo know more visit: https://bit.ly/3xVKqN8
URL:http://www.pharmajournalist.com/event/reuters-events-pharma-2022/
LOCATION:Nice Acropolis Convention Center\, Nice\, France
ORGANIZER;CN="Reuters Events":MAILTO:Matt.atkinson@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221010
DTEND;VALUE=DATE:20221012
DTSTAMP:20260515T212146
CREATED:20220511T084634Z
LAST-MODIFIED:20220511T084634Z
UID:34048-1665360000-1665532799@www.pharmajournalist.com
SUMMARY:SAE Media Group's 3rd Annual Wearable Injectors and Connected Devices Conference
DESCRIPTION:SAE Media Group’s 3rd Annual  \nWearable Injectors and Connected Devices Conference \n10 – 11 October 2022 | London\, UK \nhttp://www.wearable-injectors.co.uk/Pharmajournalist \nThe Latest Innovations In Digital Health And On-Body Drug Delivery For The Pharmaceutical Industry \nSAE Media Group’s 3rd annual Wearable Injectors and Connected Devices Conference will explore on-body device design and development whilst also engaging in the latest advances in connectivity and digital health applications for wearable devices with industry perspectives from big pharma representatives. The conference will consider key developments in the wearable injectors field\, including the enhanced demand for on-body injectors and digitalised health as the need for at home self-administration and routes for delivery of time-dependent\, high volume and viscous drugs grow. \nBenefits of Attending: \n\nEngage with key regulatory updates surrounding digital health and medical devices\nDiscover advances in device design and development for large volume delivery via on-body injectors\nExplore the key drivers of novel drug products for the development for on-body injectors\nHear insights into the growing potential of digital health to improve patient experience and treatment\nDevelop your understanding of design strategies for connectivity and digital health\n\nDelegates will have the opportunity to network with the following companies: \n\nJohnson & Johnson\nBiogen\nAstraZeneca\nMerck KGaA\nNovartis\nNovo Nordisk\nBoehringer Ingelheim\n\nAnd many more!! \nWho Should Attend: \n\nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of:\nDrug-Delivery Developers\nAutoinjectors\nDevice Engineering\nHuman Factors\nInjectables\nPackaging\nRegulatory Affairs\nConnectivity\nMedical Device Data\nNovel Product Technology\nSmart Device Developers\nDevice Safety Solution Providers\nor anyone who works with Wearable Devices/ On-Body Injectors within pharmaceuticals\, biotech\, device developers and solution providers.\n\nThe two-day conference will bring you high-quality insights and industry connections on the latest advances in wearable injectors and connectivity\, and a platform for exchanging ideas. \nFor more information contact: \nNikisha Galoria | Marketing Executive | SAE Media Group \nEmail: ngaloria@smi-online.co.uk \nPhone: +44 (0) 20 7827 6164 \nFollow us on: \nLinkedIn: SAE Media Group Pharma \nTwitter: @SAEMGPharma
URL:http://www.pharmajournalist.com/event/sae-media-groups-3rd-annual-wearable-injectors-and-connected-devices-conference/
LOCATION:London\, UK
ORGANIZER;CN="Hanson Wade":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221005
DTEND;VALUE=DATE:20221007
DTSTAMP:20260515T212146
CREATED:20220630T101923Z
LAST-MODIFIED:20220630T102012Z
UID:34567-1664928000-1665100799@www.pharmajournalist.com
SUMMARY:2nd Annual Next Generation Pharmaceutical Cleanroom
DESCRIPTION:2nd Annual Next Generation Pharmaceutical Cleanroom \n5 – 6 October 2022\nLondon\, UK\nhttp://www.nextgen-pharmacleanroom.com/PJwl \nSponsored by Ecolab\, Elis Cleanroom\, Innerspace\, Microgenetics\, Novatek \nCo-Chaired by: Conor Murray\, Chairman\, Irish Cleanroom Society and Connor McMorrow\, Aseptic Lead Cell Therapy\, Takeda  \nAdvances in Pharma 4.0 for an Improved\, Efficient and Contaminant-Free Cleanroom \nSAE Media Group are pleased to announce the 2nd Annual Next Generation Pharmaceutical Cleanroom Conference. An event that focuses on cleanroom technology in the pharmaceutical industry\, the conference will serve to bridge that gap between the two areas while simultaneously providing a unique selling point. \nThis one-of-a-kind meeting will facilitate networking opportunities with key opinion leaders from all areas of pharmaceuticals\, biologicals\, and cleanroom industry experts to explore hot topics within cleanroom design and engineering\, best practices and regulation\, environmental and contamination control\, and pharmaceutical microbiology. \nIn 2025\, the global cleanroom technology market is expected to reach nearly $5 billion. Stringent regulatory standards for product approvals\, technological advancements in cleanrooms\, initiatives taken by private organisations to create awareness regarding cleanroom and growth of the healthcare sector globally are among the few factors expected to drive the market. \nThis event will look in-depth at the significant change that the cleanroom industry is going through. From the new operating practices that keep the product as sterile as possible\, to the developments in technology that are enabling this to happen. Whether through robotics\, automated disinfection\, or data driven environmental monitoring- this conference will highlight the developments that are fundamentally changing the industry. \nEvent Hashtag: #PharmaCleanrooms \nKey Reasons to attend: \n\nLearn how to maximise the latest cleanroom technologies to modernise your contamination control strategy\nMaximise the cost-effectiveness of your cleanroom and navigate best practises for cleanroom design\nOptimise your preparation for upcoming regulatory changes\, including the impending Annex 1\nIncrease your cleanroom availability & accessibility through streamlined approaches to contamination control\n\nWHO SHOULD ATTEND: \nSenior Micro Manager\, QC Manager\, Quality Director\, Clean Room Design Managers\, Design\, Qualify and Testing – Clean Room (across the board)\, Head of Clean Room Technologies\, Head of Compounding Pharmacies\, Head of Clinical Drug Products\, Head of Clinical Medical Device \nView the brochure and to download visit http://www.nextgen-pharmacleanroom.com/PJwl
URL:http://www.pharmajournalist.com/event/2nd-annual-next-generation-pharmaceutical-cleanroom/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221004
DTEND;VALUE=DATE:20221007
DTSTAMP:20260515T212146
CREATED:20220630T094848Z
LAST-MODIFIED:20220630T094848Z
UID:34555-1664841600-1665100799@www.pharmajournalist.com
SUMMARY:4th Macrophage-directed Therapies Summit
DESCRIPTION:4th Macrophage-directed Therapies Summit\, taking place from 4-6 of October in Boston\, will bring together professionals to accelerate the clinical validation of macrophage-directed therapies\, manipulating and fixing phenotypic plasticity to develop safe\, targeted therapies for oncology\, autoimmunity\, inflammation and beyond. \nJoin your peers in person and delve into: \n\nCD47 targeting and other ‘don’t eat me’ signals\nSafety concerns due to model translatability and dosing\nOptimal combination or monotherapy discovery\n\nYou can view the event guide here: https://ter.li/ezyi0h \nSecure your place at the summit here: https://ter.li/x9p0ua \nWe are looking forward to welcoming you to Boston this October!
URL:http://www.pharmajournalist.com/event/4th-macrophage-directed-therapies-summit/
LOCATION:Crowne Plaza Boston Woburn\, 15 Middlesex Canal Park Dr\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221004
DTEND;VALUE=DATE:20221007
DTSTAMP:20260515T212146
CREATED:20220610T091530Z
LAST-MODIFIED:20220610T091530Z
UID:34394-1664841600-1665100799@www.pharmajournalist.com
SUMMARY:2nd Rare and Genetic Kidney Drug Development Summit
DESCRIPTION:Uniting industry experts dedicated to accelerating the frontier of transformative therapeutics\, the 2nd Rare & Genetic Kidney Disease Drug Development Summit is the definitive industry forum sharing cross-industry insight to understand genetic drivers of disease\, uncover early biomarkers of efficacy\, and navigate disease specific endpoint development. \nFrom clarifying molecular characteristics to reclassify disease subtypes to enrolling patient cohorts in rare disease populations\, join industry experts in-person from Travere Therapeutics\, FDA\, Sanofi\, Chinook Therapeutics\, Goldfinch Bio\, Takeda\, Regulus Therapeutics\, Otsuka and many more to accelerate life-changing therapeutics for the treatment of ADPKD\, ARPKD\, IgA\, FSGS\, Alport Syndrome. \nTo know more visit: https://ter.li/rzowfh
URL:http://www.pharmajournalist.com/event/2nd-rare-and-genetic-kidney-drug-development-summit/
LOCATION:Hilton Woburn\, 2 Forbes Road\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:(+1) 617 455 4188
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221003
DTEND;VALUE=DATE:20221006
DTSTAMP:20260515T212146
CREATED:20220623T103213Z
LAST-MODIFIED:20220623T103213Z
UID:34498-1664755200-1665014399@www.pharmajournalist.com
SUMMARY:LEAP TA: Life Sciences 2022
DESCRIPTION:The Definitive Event to Transform Your Internal Impact & Differentiate Your Employer Brand to Attract the in-Demand Biopharma Talent Required to Fast-Track Business Innovation & Growth \nNow in its fourth year\, LEAP TA: Life Sciences is the only forum dedicated to helping established and emerging life sciences organizations operating in the US who are breaking away from traditional TA to develop high functioning TA teams bursting to inspire talent needed to drive mission-critical innovation. \nIt is a unique opportunity to engage in a genuinely disruptive dialogue with your peers around what TA tech tools are really worth the investment and the radical new talent acquisition strategies required to address how life sciences organizations will deal with the fallout of the tight talent market in 2022 and beyond. \nDesigned for anyone with a stake in talent acquisition at the heart of biopharma businesses of all sizes\, those who take part will find out how to rewrite the rules of talent acquisition to balance speed with fit in finding brilliant people to gain a sustainable competitive advantage. \nSo\, whether you work in the newest start-up biotech or the largest big pharma company\, there’s something at this event for you. Secure your place now to save time\, money and add vital efficiencies to your talent acquisition activities. \nTo know more visit: https://bit.ly/3HO1Tdv
URL:http://www.pharmajournalist.com/event/leap-ta-life-sciences-2022/
LOCATION:Embassy Suites by Hilton Boston at Logan Airport\, 207 Porter St\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220926
DTEND;VALUE=DATE:20220929
DTSTAMP:20260515T212146
CREATED:20220531T070301Z
LAST-MODIFIED:20220531T070301Z
UID:34307-1664150400-1664409599@www.pharmajournalist.com
SUMMARY:4th RAS-Targeted Drug Development Summit
DESCRIPTION:For decades\, RAS has existed as an elusive therapeutic target\, and drugging this high-value oncogene was deemed impossible. Despite this\, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is\, in fact\, druggable and that drugging this protein unlocks a world of successful therapeutic interventions. The future looks bright for treating patients with cancers harboring the RAS mutation. \nThe 4th RAS-Targeted Drug Development Summit returns as the definitive industry dedicated forum for the whole community of individuals committed to targeting RAS. Bigger and better than ever before\, we will unite 300+ experts to showcase 3-days of exclusive\, never shared before data as we delve into accelerating discovery and emerging strategies\, optimizing translation and pre-clinical development\, and advancing the landscape of clinical trials for combinations and monotherapies. \nWith mounting success in targeted RAS drugs\, leading frontiers and experts must unite and continue accelerating the applications of this therapeutic for patients in need.  Through novel data\, expert insight\, and exclusive discussions with global leaders\, we will facilitate vital learnings to progress RAS therapeutics to drug all-mutations from G12C\, G12D\, and G12V. Continuing to advance valuable combination therapies into the clinic\, and finally\, crack resistance to RAS targeted therapeutics. \nAccess the official agenda for more information. \nEarly-bird & team discounts available – Secure your place today.
URL:http://www.pharmajournalist.com/event/4th-ras-targeted-drug-development-summit/
LOCATION:Marriott Burlington\, One Burlington Mall Road\, Burlington\, MA\, 01803\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220921
DTEND;VALUE=DATE:20220923
DTSTAMP:20260515T212146
CREATED:20220404T083554Z
LAST-MODIFIED:20220404T083554Z
UID:33687-1663718400-1663891199@www.pharmajournalist.com
SUMMARY:Oligonucleotide Therapeutics and Delivery Conference 2022
DESCRIPTION:Part of the 13th annual RNA Therapeutic series of events\nSMi’s 2nd Annual Conference \nOligonucleotide Therapeutics and Delivery Conference 2022\nDate: 21st – 22nd September 2022\nLocation: London\, UK\nWebsite: www.oligonucleotide.co.uk/PharmaJournalist \nAdvancements in extra-hepatic delivery of oligonucleotides \nThe Oligonucleotide Therapeutics and Delivery conference reveals the latest in oligonucleotide discovery and delivery\, with presentations on targeted delivery mechanisms\, oligonucleotide chemistries and important clinical advances. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of oligonucleotides with case studies surrounding the discovery and development of oligonucleotide therapeutics as well as CMC and regulatory standpoints. The two-day conference will bring you high-quality insights and industry connections on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. \nEstablished on the success of our RNA Therapeutics series\, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments. \nBenefits of attending: \n\nListen to case studies presenting on pre-clinical and clinical research in areas such as oncology and what can be learned for future clinical trials\nDeepen your understanding of oligonucleotide therapeutic delivery and explore the latest innovations in extrahepatic oligonucleotide delivery and target specificity\nUnderstand the regulatory and CMC environment surrounding oligonucleotide therapeutic development\nExplore developments in oligonucleotide chemistries and examine developments in novel applications of antisense oligonucleotides and siRNA\nEngage in the latest innovations in oligonucleotide therapeutics such as utilising AI machine learning to drive the discovery of novel therapeutics\n\nPlus\, two interactive half day pre-conference workshops on 20th September 2022: \n\nOligonucleotide Therapies- Overcoming The Challenges Of Delivery led by Nick Lench\, Executive Director\, NATA\, Martin Kerr\, Head of Business Development & Partnerships\, Nucleic Acid Therapy Accelerator\, Ritwick Sawakar\, MRC Investigator\, MRC Toxcology Unit\, University Of Cambridge\nManaging CMC Activities For The Development Of Oligonucleotide Therapeutics led by Mia Kiistala\, CEO/Owner/Principal Consultant\, Aurora CMC Consulting \n\nCHAIRS FOR 2022: \n\nEkkehard Leberer\, Senior Life Sciences Consultant\, Elbicon\njimmy Weterings\, Principal Scientist\, AstraZeneca \n\nFEATURED 2022 SPEAKERS INCLUDE:  \n\nShalini Anderson\, Vice President Oligonucleotide Discovery\,AstraZeneca\nHeinrich Haas\, Vice President RNA Formulation & Drug Delivery\, BioNTech\nTamar Grossman\, Global Head of RNA and Targeted Therapeutics\, Janssen pharmaceuticals\nSarahTabrizi\,Director of UCL Huntington’s disease centre\, UCL Institute of Neurology\nMacarena Hernandez-Jimenez\, Chief Scientific Officer\, AptaTargets\nDavid Evans\, Chief Scientific Officer\, Sirnaomics\nNick Lench\, Executive Director\, Nucleic Acid Therapy Accelerator\nBart Anderson\,Senior Director of R&D\, Exicure\n\nWho should attend: \nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of: \n\nRNA Biology/Discovery\nNovel Therapeutic Modalities\nInnovation Technologies\nC-level Scientific Executives\nFormulation and Drug Delivery\nClinical Research and Development\nCell Biology\n\nEARLY-BIRD RATES: \n\nBOOK BY 29TH APRIL AND SAVE £400\nBOOK BY 31ST MAY AND SAVE £300\nBOOK BY 30TH JUNE AND SAVE £200\n\nAdditional Contact Info: \nT: +44 (0)20 7827 6154 \nE: ngaloria@smi-online.co.uk \nLinkedIn: SMi Pharma \nTwitter: @SMiPharma | #SMiOligonucleotides  \nKeywords: \nSmall interfering RNA\, siRNA\, Antisense therapy\, DNA\, RNA\, nucleic acid\, mRNA\, Micro RNA\, RNA-induced silencing complex\, RISC\, Aptamers\, oligonucleotide\, peptide molecules\, Immunogenicity\, Drug pipeline\, short interfering RNA\, silencing RNA\, RNA interference\, RNAi\, mRNA degradation \nHashtags:  \n#SmallinterferingRNA\, #siRNA\, #Antisensetherapy\, #DNA\, #RNA\, #nucleicacid\, #mRNA\, #MicroRNA\, #RNAinducedsilencingcomplex\, #RISC\, #Aptamers\, #oligonucleotide\, #peptidemolecules\, #Immunogenicity\, #Drugpipeline\, #shortinterferingRNA\, #silencingRNA\, #RNAinterference\, #RNAi\, #mRNAdegradation
URL:http://www.pharmajournalist.com/event/oligonucleotide-therapeutics-and-delivery-conference-2022/
LOCATION:London\, UK
ORGANIZER;CN="SMi Events":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220920
DTEND;VALUE=DATE:20220922
DTSTAMP:20260515T212146
CREATED:20220720T075747Z
LAST-MODIFIED:20220720T075747Z
UID:34728-1663632000-1663804799@www.pharmajournalist.com
SUMMARY:Reuters Events: Cell & Gene Therapy USA 2022
DESCRIPTION:Co-create a commercial toolkit that enables suitable\, scalable and sustainable growth.  \nWith over 20 CGTs projected to be approved by 2025\, it’s clear that there are huge commercial and medical opportunities for precision medicine. But despite this unprecedented growth\, unstable infrastructure\, lack of standardization and novel scientific nuance means that there is still no industry blueprint for successful commercialization. \nTo realize this potential\, precision medicine trailblazers must share lessons of launch success and overcome pain points to allow pharma to reinforce frameworks across manufacturing\, market access and reimbursement to build infallible launch strategies across the board. Commercialization networks must go even further\, transforming our healthcare system to guarantee scalable and sustainable growth.     \nDon’t get left behind.   \nJoin us at Reuters Events: Cell and Gene Therapy USA where we have leaders from industry front runners to share their successes and pitfalls. With 30+ speakers\, 5 case-studies and over 1500+ fellow CGT attendees – we will pioneer a new gold standard for commercialization\, readying the world for CGT as a frontline treatment. \nTo know more visit: https://bit.ly/3oepDP3
URL:http://www.pharmajournalist.com/event/reuters-events-cell-gene-therapy-usa-2022/
LOCATION:Virtual
ORGANIZER;CN="Reuters Events":MAILTO:daisy.beale@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220920
DTEND;VALUE=DATE:20220923
DTSTAMP:20260515T212146
CREATED:20220607T100621Z
LAST-MODIFIED:20220607T100621Z
UID:34368-1663632000-1663891199@www.pharmajournalist.com
SUMMARY:2nd NSCLC Drug Development Summit
DESCRIPTION:Advances in molecular and immunohistochemical techniques have ushered the NSCLC space into an exciting era of personalized medicine and improved outcomes – and a plethora of novel therapies are now in clinical development. Despite this\, and whether patients fit into one of the actionable alteration subtypes of NSCLC or not\, most will progress and/or develop resistance to currently available treatments. \nNSCLC remains one of the highest tumor indications of unmet clinical need\, with prevalence only set to increase. Focusing from late-line through to early-line\, this conference will address how to supercharge your pipeline through implementing smart drug design; expert translational medicine; advanced trial design and patient recruitment; and evidence-based combination and sequencing rationale specific to NSCLC. \nThe 2nd NSCLC Drug Development Summit returns as the only industry-led forum for large biopharma\, biotech and academic leaders to address mechanisms of drug resistance\, spearhead progress in molecular subtyping and define practice-changing drug sequencing and combinations for the largest solid tumor indication. \nWe will be focusing on: \n\nRefining molecular testing of NSCLC tumors and making next-generation sequencing tools more accessible in the clinical setting\nInvestigating novel immune checkpoints and checkpoint inhibitor sequencing or combinations with surgery\, chemo and/or radiotherapy where applicable\, to define therapeutic options with better safety and efficacy outcomes in second line or beyond\nOvercoming resistance mechanisms and patient progression after TKI treatment approaches for NSCLC tumors with actionable alterations\nProviding clarity on tumor biopsy testing guidelines to promote effective personalized treatment of patients\nIdentifying truly transformative investigational drugs for use in the early vs. late-stage NSCLC setting and cut through the noise of increasingly complex therapeutic options\nExploring trial design challenges to watch out for and tips for patient inclusion/exclusion criteria\n\nJoin the NSCLC Summit for 3 jam-packed days of presentations\, panel discussions and interactive workshops with over 20 expert industry speakers. \nThere has never been a more important time to rally together to defeat NSCLC and radically change patients lives. \nTo know more visit: https://bit.ly/3mpftud
URL:http://www.pharmajournalist.com/event/2nd-nsclc-drug-development-summit/
LOCATION:Boston\, MA (venue TBC)
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220920
DTEND;VALUE=DATE:20220923
DTSTAMP:20260515T212146
CREATED:20220519T110535Z
LAST-MODIFIED:20220908T090420Z
UID:34139-1663632000-1663891199@www.pharmajournalist.com
SUMMARY:mRNA Process Development & Manufacturing Summit
DESCRIPTION:The mRNA Process Development & Manufacturing Summit will be taking place in-person in Boston\, MA this month (September 20 – 22\, 2022). The only conference roadmap to accelerate mRNA drug substance process scale up and manufacturing! \nThis conference will showcase the pioneering work of 30+ global leaders across 3 days of immersive content sharing new data\, allowing you to stay ahead of the curve. \nIf you and your team are looking to learn how to overcome mRNA process scale up and manufacturing hurdles towards regulatory harmonization by optimizing in vitro transcription\, purification\, and analytical validation of your mRNA drug substance\, then you should attend this dedicated industry forum to see the outlook to this advancing and dynamic field. \nMultiple functions from 75+ leading companies and their teams have already registered\, here’s just a snapchat: \n\nDirector – Business Development mRNA Therapeutics\nSenior Director – Manufacturing Science & Technology\nHead of Quality\nPrincipal Applications Scientist – mRNA\nDirector – Formulation and Drug Delivery\nPrincipal Scientist – Early Bioprocess\nSenior Process Development Associate – mRNA\nGroup Leader (RNA Reagents) – Production\nDownstream Scientist – Technical R&D\nScientist II – Analytical Development\nDirector – RNA Therapeutics Development R & D\nDirector – CMC RNA Vaccines Biopharmaceutical Development\nAssociate Director – Drug Substance\nSenior Director – CMC Reg Affairs Regulatory\n\nWith very limited passes remaining\, register today and be part of the conversation. \nTo know more visit: https://ter.li/9v5h9k
URL:http://www.pharmajournalist.com/event/mrna-process-development-manufacturing-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220919
DTEND;VALUE=DATE:20220921
DTSTAMP:20260515T212146
CREATED:20220524T091925Z
LAST-MODIFIED:20220524T091925Z
UID:34218-1663545600-1663718399@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes San Francisco
DESCRIPTION:SAE Media Group’s 3rd Annual Conference\nSeptember 19 – 20\, 2022 | San Francisco\, CA\, USA\n————————————————————————- \nThe pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics\, high concentration\, and large-volume drug products. \n \nThis year’s conference will be assessing the latest developments in new technologies for next generation device design\, including computational simulation approaches forming the digital revolution of devices design. Furthermore\, the latest advances in digital combination product development will be explored through the lens of lifecycle management and user-centric combination products. Leading experts from big pharma will be presenting case studies on recent advances in platform approaches in drug delivery devices and smart devices\, while a panel discussion will explore the emerging opportunities of platforms for injectable devices. With recent developments in industry regulations and guidance\, the 2022 agenda will give an international insight into the global regulatory environment and leading FDA representatives will address the key standards to be aware of in injectable device development.  \nOver recent years we have seen the need for injectable devices to adapt to novel therapeutics. Our expert industry thought leaders will present case studies and updates to the industry’s approach to injectable delivery for novel drug products. Furthermore\, our speakers will be assessing the key considerations for primary packaging and CMC approaches to injectable device development.  \nAs part of SAE Media Group’s leading injectable drug delivery portfolio\, this event is not to be missed. \nThe two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nTo know more visit: http://www.prefilled-sanfrancisco.com/pharmajournalistwl
URL:http://www.pharmajournalist.com/event/pre-filled-syringes-san-francisco-2022/
LOCATION:Hyatt Centric\, Fisherman’s Wharf\, San Francisco\, CA\, 94133\, United States
ORGANIZER;CN="SAE Media Group":MAILTO:richard.jones@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220919
DTEND;VALUE=DATE:20220921
DTSTAMP:20260515T212146
CREATED:20220523T112249Z
LAST-MODIFIED:20220523T112249Z
UID:34202-1663545600-1663718399@www.pharmajournalist.com
SUMMARY:2nd Annual Aseptic Processing Conference
DESCRIPTION:2nd Annual Aseptic Processing Conference  \nConference: 19 – 20 September 2022\nWorkshop: 21 September 2022 \nLondon\, UK\nhttp://www.asepticprocessing.co.uk/PJWL \n \nSponsored by: Dec Group\, Rapid Micro Biosystems\, Raumedic and STERIS\n\nConference Chairman: James Drinkwater\, Head of Aseptic Processing Special Interest Group PHSS and Head of GMP Compliance\, F Ziel GMBH \nDriving a Holistic Approach to Assurance of Product Sterility through Aseptic Manufacturing following QRM Principles \nSAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference\, this year taking place in London\, on the 19 and 20 September 2022. \nThe Aseptic processing industry has seen consistent growth in recent years\, with advances in innovative therapeutics\, the introduction of novel techniques and personnel protocols\, the integration of robotics and automation in filling lines\, and rise of rapid microbiological methods being just a few of the factors driving this growth. \nThe Aseptic Processing equipment market was approaching a valuation of 10 billion USD in 2015\, and is projected to exceed 12 billion USD in value by next year\, then to far surpass a total market value of 50 billion USD before the end of the decade. \nJoin us to discuss and address the  Guidance and Regulation including the EU GMP Annex 1\, environmental control delving into the contamination control strategy\, Pharma moving forward 4.0 covering data integrity and data consistency\, robotics in aseptic processing and exploring the continued aseptic processing development in Annex 1 and environmental monitoring \nThis event is CPD Accredited  \nEvent Hashtag: #AsepticProcessing  \nBenefits of Attending: \n\nDiscuss the revisions and the impact of Annex 1 on aseptic manufacturing\nExplore the applications of rapid micro methods in the manufacture of sterile products\nDiscover a risk-based approach to cleaning and disinfection\nDelve into case studies of competence in global aseptic manufacturing\nUncover the journey of isolation technology in a large biotech pharmaceutical plant\nAnalyse the new abilities of robotics and automation through their integration into aseptic technique\n\n Who Should Attend? \n\nValidation Managers\nSenior Microbiologists\nSenior QA’s and QC’s\nQuality Control Managers\nHeads of GMP Compliance\nQuality Assurance Experts\nTechnical Operations Leads\nLeaders in Sterility Assurance\nCleanroom Managers\nRegulatory Affairs Managers\nProduction Managers\nQuality Systems Managers\nHeads of Quality Compliance\nProcess Leaders\nSenior Auditors\nBioprocess Research & Development\n\n PLUS – Post-Conference Workshop on 21 September 2022… \nImplementation Strategy of Annex 1 in New or Existing Facilities \nLed by: Richard Denk\, Senior Consultant Aseptic Processing & Containment\, Skan AG \nView the brochure and to download visit http://www.asepticprocessing.co.uk/PJWL
URL:http://www.pharmajournalist.com/event/2nd-annual-aseptic-processing-conference/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220919
DTEND;VALUE=DATE:20220924
DTSTAMP:20260515T212146
CREATED:20220317T083147Z
LAST-MODIFIED:20220317T083147Z
UID:33597-1663545600-1663977599@www.pharmajournalist.com
SUMMARY:7th CAR-TCR Summit
DESCRIPTION:Back to Boston with a bang! With 1\,500 CAR and TCR developers\, 200 speakers\, 150 live presentations\, 20 hours of networking and more surprises in store\, the 7th CAR-TCR Summit will be the BIGGEST ever. \nGain end-to-end insights from industry giants and the innovators bringing disruptive technologies from bench to bedside and from vein to vein. \nDiscuss everything from novel allogeneic approaches with enhanced safety considerations\, the latest in vivo gene engineering techniques\, and advances in CMC and analytics to ensure the development of high-quality cell products. \nWith your industry reuniting in-person for the first time since 2019 to discuss leveraging the powerful potential of iPSC platforms\, learnings from our successes and pitfalls\, and manufacturing automation innovations for large scale consistent production\, you can’t afford to miss the 7th Annual CAR-TCR Summit as we bring you more speakers\, more content and more exclusive insights than ever before! \nTo know more visit: https://ter.li/km5zwy
URL:http://www.pharmajournalist.com/event/7th-car-tcr-summit/
LOCATION:Boston\, MA
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220913
DTEND;VALUE=DATE:20220916
DTSTAMP:20260515T212146
CREATED:20220620T111850Z
LAST-MODIFIED:20220620T111850Z
UID:34473-1663027200-1663286399@www.pharmajournalist.com
SUMMARY:5th Microbiome Movement – Skin Health & Dermatology Summit
DESCRIPTION:Translating Scientific Methodologies Addressing the Skin Microbiome into Commercially Viable Dermatological Therapeutics & Cosmetic Products \nSkin microbiome research is continuing to gain increasing market traction from a number of stakeholders\, including drug developers and cosmetic brands. For investment and progress to continue\, it is vital to meet and connect with the key opinion leaders in the space. \nNow in its fifth year\, the Microbiome Movement – Skin Health & Dermatology Summit will unite the field’s leaders from academia and industry to address the unique scientific and commercial challenges of working in the skin microbiome. This meeting will provide a platform for crucial discussions which will hasten the development of microbiome-targeting therapeutics and cosmetics that focus on characterization\, clinical testing\, and product commercialization. \nThis is your opportunity to connect with 100+ collaborative thought leaders in the skin microbiome field from academics\, drug developers\, cosmeceutical developers\, cosmetic and consumer brands\, to obtain a holistic view of the microbiome dermatology landscape that will revolutionise your product pipeline. \nFind out more about the meeting\, who’s attending and what you could learn by downloading the latest event guide: https://ter.li/nzhrvy \nOr become one of our event partners and showcase your company’s latest technologies and solutions! Get in touch with us directly or request a partnership prospectus here: https://ter.li/9kybuv \nWe look forward to welcoming you to Boston in September!
URL:http://www.pharmajournalist.com/event/5th-microbiome-movement-skin-health-dermatology-summit/
LOCATION:Four Points by Sheraton Boston Logan Airport Revere\, 407 Squire Rd\, Revere\, MA\, 02151\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@microbiome-movement.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220913
DTEND;VALUE=DATE:20220917
DTSTAMP:20260515T212146
CREATED:20220516T094442Z
LAST-MODIFIED:20220516T094442Z
UID:34110-1663027200-1663372799@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Ophthalmic Disorders
DESCRIPTION:Revolutionizing Genetic Therapy Development & Delivery to the Eye \nDiscovering Next Generation Administration Routes for the Eye; Overcoming the Translational Challenges of Ophthalmic Preclinical Models; & Discussing Toxicity & Targeting Challenges of Vector-Based Approaches \nThe ophthalmology field is bursting with novel genetic approaches for targeting many disorders\, with gene therapy taking centre stage as a one-time treatment option. With more invasive subretinal approaches being used in the clinic\, as well as more innovative outpatient methods such as suprachoroidal delivery\, there are a lot of pros and cons to discuss as the field progresses towards developing efficacious and durable treatments for many ophthalmic disorders. \nReturning for its 3rd year\, the Gene Therapy for Ophthalmic Disorders is the definitive forum for those working on ophthalmic gene therapy. This is the only conference that unites pharma and biotech to address the most pressing challenges\, with focus on discussing and sharing solutions with the key leaders in the industry. \nThis year we have expanded into two streams of learning\, putting more emphasis on the individual challenges faced in both the preclinical and clinical phases of ophthalmic gene therapy drug development. \nGene therapy for ophthalmic disorders has only seen one FDA approved therapy\, which drug will be the next? Join 150+ of your peers to discuss and overcome the barriers preventing drugs getting to market. \nLeave the definitive 3rd Annual Gene Therapy for Ophthalmic Disorders forum equipped with knowledge of novel methods and developments\, actionable lessons learned and new connections. Don’t miss your opportunity to be a part the conversation which could lead to the next drug approval.
URL:http://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-ophthalmic-disorders/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220906
DTEND;VALUE=DATE:20220909
DTSTAMP:20260515T212146
CREATED:20220713T080736Z
LAST-MODIFIED:20220713T080736Z
UID:34660-1662422400-1662681599@www.pharmajournalist.com
SUMMARY:5th International Cannabinoid-Derived Pharmaceuticals Summit
DESCRIPTION:Over the last half-decade\, we have witnessed game-changing developments within the cannabinoid field\, driving it into a new era of rigorous research\, promising clinical trials and multimillion-dollar deals. Right now\, there are 50 cannabinoid therapeutic trials taking place at phases 2 and 3\, pushing for approval to meet the clinical needs of patients with chronic pain\, cancer\, psychiatric conditions and much more. Despite these positive changes and rapid industry growth there remains key challenges to overcome for drug developers regarding the human evidence gap\, funding and changing regulation – to name just a few. \nThe 5th International Cannabinoid-Derived Pharmaceuticals Summit is uniting drug developers\, investors\, solution providers and academics from around the globe working to overcome these challenges and progress the field of cannabinoid therapeutics. 35+ expert speakers will lead sessions on critical topics across 3 days of presentations\, panel discussions and interactive workshops in Boston. \nAgenda highlights include: \n\nPresent a poster of your drug development pipeline at our investor networking session\, and connect with the decision makers looking to fund promising cannabinoid therapeutics\nGet the most up-to-date regulatory perspectives from the FDA and other organizations with Dominic Chiapperino (FDA) and Cassie Taylor\n(FDA)\nProduce and source high-purity cannabinoids from synthetic\, plant-based and biosynthetic sources with Purisys\, Kinetochem and our other world-leading partners\nHear from the key opinion leaders at the forefront of next-generation cannabinoid-derived pharmaceutical development including Alistair Vickery (Emyria)\, Brian Murphy (Former CEO of Emerald Bioscience) and Jeff Chen (Radicle Sciences)\nStreamline successful late-stage clinical trials and be the next one across the finish line with a multi-format and highly interactive session with Sud Agarwal (Cannvalate)\nJoin 2 half-day workshops – one dedicated to bridging the gap between OTC and prescribed pharmaceuticals\, and an additional behind-the-scenes workshop on the psychedelics field\, preparing you for exploration into a new area\nConnect with 80+ thought leaders and industry peers as they come together to drive discussion and progress across the 3-day event\n\nThe Summit focuses on the real science in the cannabinoid industry and is the only chance to connect with likeminded\, analytical professionals looking to move the dial forward in this exciting space. Check out the event guide for the full agenda
URL:http://www.pharmajournalist.com/event/5th-international-cannabinoid-derived-pharmaceuticals-summit/
LOCATION:Boston\, MA (venue TBC)
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220906
DTEND;VALUE=DATE:20220909
DTSTAMP:20260515T212146
CREATED:20220524T085905Z
LAST-MODIFIED:20220524T085905Z
UID:34213-1662422400-1662681599@www.pharmajournalist.com
SUMMARY:Optimizing AAV Safety Summit
DESCRIPTION:Hundreds of clinical trials using AAV are underway\, with several hundred more in preclinical development. Given the sheer volume of studies in the pipeline\, the need to administer high doses\, the clinical holds placed on gene therapy trials\, and regulatory bodies being increasingly stringent on the safety standards they require; it has never been more important to create and implement an AAV safety strategy that’s fit for purpose! \nIn this setting\, the inaugural Optimizing AAV Safety Summit is bringing together key leaders focussed specifically on solving AAV safety challenges across toxicology\, pharmacology\, non-clinical study leads\, clinical development safety specialists and bioanalysis innovators to gain insights on optimizing AAV safety processes and benefit-risk analysis to shorten timelines and prevent potential delays. \nJoin us in Boston alongside key biotech and pharma leaders from the likes of Spark Therapeutics\, Ask Bio\, Eli Lilly\, Takeda\, and more in the AAV space who are prioritizing the development of safe and effective genetic therapies\, learn how clinical safety signals have changed how companies are approaching their pipeline progression\, and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development. \nTo know more visit: https://ter.li/r92wow
URL:http://www.pharmajournalist.com/event/optimizing-aav-safety-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220830
DTEND;VALUE=DATE:20220902
DTSTAMP:20260515T212146
CREATED:20220526T182710Z
LAST-MODIFIED:20220526T182710Z
UID:34236-1661817600-1662076799@www.pharmajournalist.com
SUMMARY:2nd Integrin-Targeted Drug Development Summit
DESCRIPTION:Over the last 12 months\, the industry has witnessed promising data and candidates entering the clinic. 7 Hills Pharma\, Corbus Pharmaceuticals\, Vincerx\, and Morphic are paving the way to develop a safe\, efficacious integrins-targeted drug to modify disease biology\, which will be a game-changer for diseases such as oncology\, autoimmune\, and ophthalmology\, with unmet medical needs. \nIn collaboration with leading integrin drug developers\, including Genentech\, 7 Hills Pharma\, and Pfizer\, the 2nd Integrin-Targeted Drug Development Summit is designed for industry leaders to unite and outline clinical strategies for success\, including patient selection biomarkers and dosing. \nGet your critical questions answered to supercharge your clinical programs\, direct your drug pipelines and ensure you take lessons learned to successfully modulate integrins to improve treatment regimens in chronic\, familiar\, and rare diseases.  \nJoin us for this 3-day summit to gain unparalleled insights and experience first-hand from integrin drug developers to accelerate your candidate into the clinic and develop a first-in-class treatment option by modifying underlying disease biology for our patients. \nTo know more visit: https://ter.li/qoq74v
URL:http://www.pharmajournalist.com/event/2nd-integrin-targeted-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220829
DTEND;VALUE=DATE:20220902
DTSTAMP:20260515T212146
CREATED:20220527T124300Z
LAST-MODIFIED:20220527T124300Z
UID:34298-1661731200-1662076799@www.pharmajournalist.com
SUMMARY:6th IPF Summit
DESCRIPTION:With two approved therapeutics and the field working to develop the next generation of IPF drugs\, the opportunity to become the undisputed\, most effective\, and disease-modifying agent on the market has never been greater. \nFrom repairing and regenerating lung tissue to illuminating innovative clinical trial design and advance scientific progress; the 6th IPF Summit is your one-stop-shop to supercharge IPF research and drug development. \nWhat’s new and unmissable for 2022: \n\n29 brand new industry speakers\, as well as returning KOLs including Fernando Martinez\, Naftali Kaminski\, Toby Maher\, and many more\n6 interactive workshops to delve into IPF’s hottest topics\, discuss challenges\, pose your burning questions to leading experts\, and highlight the respiratory pipeline development opportunities including SSc-ILD\, COPD\, and COVID fibrosis\nA brand-new Tissue Repair and Regeneration Day\, with dedicated sessions on halting and reversing disease progression to rethinking senescence to unlocking cell therapies. Get more insight than ever before on evolving basic science and regenerative therapy opportunities\nExclusive presentations on the regulatory and patient perspectives to inform clinical trial design and future therapeutic development\n\nGet in the room with your team to meet peers and KOLs and take away critical insights at the world’s most comprehensive and dedicated IPF conference. Confirmed attendees include AbbVie\, Boehringer Ingelheim\, Bayer\, BMS\, Genentech\, Galecto\, Novartis\, and Trevi Therapeutics. \nFrom navigating pathophysiology and pathobiology\, exploring all available target opportunities to leveraging synthetic control arms in clinical trials; this is a conversation you won’t want to miss to transform your IPF research. \nTo know more visit: https://ter.li/6yo2nd
URL:http://www.pharmajournalist.com/event/6th-ipf-summit/
LOCATION:Westin Boston Seaport District\, 425 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220823
DTEND;VALUE=DATE:20220826
DTSTAMP:20260515T212146
CREATED:20220526T184543Z
LAST-MODIFIED:20220526T184543Z
UID:34247-1661212800-1661471999@www.pharmajournalist.com
SUMMARY:Cell Therapy Analytical Development Summit Europe
DESCRIPTION:Cell Therapy Analytical Development Summit Europe\, taking place from 23-25 of August in London\, will bring together professionals working in CMC\, QC\, process development\, and regulatory functions. \nJoin your peers in person to: \n\nLearn to develop a successful potency assay to determine product activity\nExplore reference standards for state-of-the-art analytical development\nDiscover new technology to expand and improve your analytical toolbox\nDevelop and validate analytical methods to fulfil GMP guidelines\nStreamline final product characterisation by starting with the end in mind\n\nYou can view the event guide here: https://ter.li/nxuxfd \nSecure your place at the summit here: https://ter.li/551w6c \nWe are looking forward to welcoming you to London this August!
URL:http://www.pharmajournalist.com/event/cell-therapy-analytical-development-summit-europe/
LOCATION:Hilton London Paddington\, 146 Praed St\, London\, W2 1EE\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260515T212146
CREATED:20220526T182248Z
LAST-MODIFIED:20220526T182344Z
UID:34229-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:Targeted Radiopharmaceuticals Summit US (TRP US)
DESCRIPTION:The brand-new Targeted Radiopharmaceuticals Summit US (TRP US) is the only industry-led meeting dedicated to developing next-generation radioligands. The TRP sector has developed dramatically over the previous 18 months\, with a wave of new investment in light of Lutathera’s extraordinary performance. \nAre you part of a pharmaceutical business aiming to have their Theranostic approved? If so\, this agenda is designed to deliver you a well-rounded and complete understanding of the fast-paced radiopharmaceutical sector while also learning about the critical function of diagnostic imaging. \nHear the latest insights\, case studies\, and novel data to help accelerate the development of next-generation radioligand therapies from clinical approval to commercialization. This is the only in-person meeting to bring the discussion around the challenges and opportunities facing developers of Theranostic radioligand therapies. \nTo know more visit: https://ter.li/jtzz4q
URL:http://www.pharmajournalist.com/event/targeted-radiopharmaceuticals-summit-us-trp-us/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260515T212146
CREATED:20220518T092848Z
LAST-MODIFIED:20220518T092848Z
UID:34131-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:iPSC Manufacturing Summit
DESCRIPTION:With iPSCs exhibiting game-changing potential in the bid to develop an off-the-shelf therapy\, the brand-new iPSC Manufacturing Summit is the only summit dedicated to solving the manufacturing\, quality and analytical challenges hindering your iPSC-derived treatments from reaching patients. \nThis forum will unite the exclusive community advancing the production of high-quality and consistent iPSC products\, with in depth case studies aimed to develop optimal differentiation\, cryopreservation\, and analytical protocol to enhance process development to ensure it is robust\, rapid and repeatable. \nOur 17+ expert speakers will be addressing methods to enhance potency testing and cell characterization\, enhance iPSC product quality\, and integrate successful gene-editing into your manufacturing. \nTake a look at the full event guide to learn more.
URL:http://www.pharmajournalist.com/event/ipsc-manufacturing-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260515T212146
CREATED:20220509T102858Z
LAST-MODIFIED:20220509T102858Z
UID:34021-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:2nd Annual mRNA-Based Therapeutics Summit
DESCRIPTION:Do you want to be part of the largest gathering of mRNA professionals? \nThe 2nd Annual mRNA-Based Therapeutics Summit is returning in-person to Boston this July 26-28. \nExpect exclusive data from the movers and shakers in mRNA vaccine and therapy development\, 75+ world-class speakers\, 5 dedicated tracks of content and 45+ deep-dive case studies. Find out more in the full event guide: https://ter.li/yc800m \nHere’s a snapshot of the expert speakers you can hear from: \n\n​​​​Kathy Fernando\, VP\, Head of Worldwide Research\, Development and Medical Operations & Head of mRNA Scientific Planning\, Pfizer\nRegis Gervier\, Global Head\, mRNA Center of Excellence\, Sanofi\nRituparna Das\, VP – COVID Vaccines\, Moderna\nHao Chen\, Global Head of Cell & Viral Drug Substance\, GlaxoSmithKline\nJoe Payne\, Founder\, President & CEO\, Arcturus Therapeutics\nPervin Anklesaria\, Deputy Director\, HIV Vaccines & Biologics\, Bill & Melinda Gates Foundation\nManmohan Singh\, SVP – Pharmaceutical Sciences & Delivery Technologies\, Beam Therapeutics\nAkhilesh Bhambhani\, Senior Director – Biologics Drug Product Development; Tech Dev/Tech Ops\, Ultragenyx\nLiang Shang\, Senior Scientist – Vaccine Analytical\, Merck\nRussell Johnson\, VP – Formulation Research\, RVAC Medicines\nTamar Grossman\, Global Head – RNA & Targeted Therapeutics\, The Janssen Pharmaceutical Companies of Johnson & Johnson\n\nDownload the official brochure to discover why Sanofi\, Ultragenyx\, Beam Therapeutics\, Pfizer\, Moderna\, Merck\, Eli Lilly\, GSK\, and 300+ others have already secured their places.  https://ter.li/yc800m
URL:http://www.pharmajournalist.com/event/2nd-annual-mrna-based-therapeutics-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR